TCR2 Therapeutics Inc. (NASDAQ: TCRR) stock declines by 30.96% in the current market trading session. TCR2 Therapeutics is a cell therapy firm in the clinical stage that is building a pipeline of new T cell treatments for cancer patients.
>> 7 Top Picks for the Post-Pandemic Economy <<
TCRR stock’ Update
TCR2 Therapeutics published good interim findings from the gavo-cell Phase 1/2 clinical trial for mesothelin-expressing solid tumours, which is still in progress. On September 17, a dataset will be presented in an oral presentation as part of the official ESMO Press Program at the European Society for Medical Oncology (ESMO) Congress 2021.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
David Hong, deputy chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center stated that the interim gavo-cel findings released today, demonstrated continuing medical efficacy and a controllable safety profile in a group of patients who had previously had little or no effective function to their cancer’s advanced and aggressive stage. Patients with treatment-resistant cancer have few alternatives for treatment and will frequently require hospice and supportive care. The initial survival statistics from gavo-cel in patients who had previously been treated with checkpoint inhibitors and other treatments gives us hope.
Alfonso Quintás-Cardama, Chief Medical Officer of TCR2 Therapeutics commented,
From the beginning, the goal with gavo-cel was to use cell therapies to reframe solid tumour therapy. They are pleased to share findings showing clinical activity in all three mesothelin-expressing solid tumours addressed thus far, as well as tumour shrinkage in the bulk of patients who have failed multiple rounds of therapy. The progression-free surviving and overall success rates observed in patients with refractory mesothelioma administered with gavo-cel in the Phase 1 trial are very encouraging. They feel the identification of the RP2D is close at hand, based on these findings and the most recent patient who had a very mild safety profile at a cell dose of 3×108/m2. As they reach the Phase 2 expansion phase, their emphasis will move to further improving patient outcomes by investigating immune checkpoint inhibitor combinations, permitting gavo-cel re-treatment, and assessing various mesothelin expression levels.